Vienna-based molecular biology institute pioneering organoid disease models and chromosome architecture research, with 6 ERC grants and leading expertise in 3D human tissue systems.
IMBA is a leading molecular biology research institute in Vienna, operating under the Austrian Academy of Sciences, that specializes in understanding fundamental mechanisms of gene regulation, chromosome architecture, and stem cell biology. Their signature capability is organoid technology — growing miniature human organs (especially brain organoids) from stem cells to model diseases like schizophrenia, frontotemporal dementia, and neurodevelopmental disorders. They combine this with deep expertise in chromatin biology, epigenetic reprogramming, and transposon control to tackle questions about how genomes are organized, maintained, and repaired. Their work spans from basic discovery (how cells divide, how embryos reprogram) to translational applications in drug discovery and regenerative medicine.
At least 10 projects involve organoid models — MiniBrain, Mini Brains, FTD-Organoids, Schizophrenia Organoids, BLASTOID, IMPLANTATION, HCA Organoid, PhenoConnectomics, JS_SCZ, and MAD-CoV 2.
TopoGenomics, DSB Architect, MisterCHROM, and DivIDe all investigate chromosome conformation, sister chromatid cohesion, and cohesin-mediated genome organization.
TotipotentZygotChrom, Epigenome_embryo, and PIWI-Chrom study chromatin reorganization during early embryonic development and germline transposon silencing.
RiboTrace, SLAMseq, and RNA Smuggling cover RNA silencing, metabolism, and piRNA precursor export mechanisms.
REANIMA (heart regeneration), TRANSPOLOTL and AxoMatrx (axolotl limb regeneration), and EuroGCT (gene and cell therapy communication).
TOX-ANT investigates toxin-antidote selfish genetic elements in animals, bridging gene drive research with speciation mechanisms.
In the early H2020 period (2015–2018), IMBA focused on stem cell biology, regenerative medicine, and science communication, with initial forays into cerebral organoid technology through projects like Mini Brains and Spindle Brain Organoid. From 2020 onward, the research sharpened dramatically: organoid work matured into disease modeling (FTD, schizophrenia, COVID-19) and drug discovery platforms (BLASTOID), while a new major axis in chromosome topology and cohesin biology emerged through TopoGenomics, DSB Architect, and MisterCHROM. The recent keyword dominance of "cohesin," "sister chromatids," and "organoids" — replacing earlier broad terms like "science communication" and "stem cell research" — signals a transition from foundational biology toward mechanistic, disease-relevant applications.
IMBA is converging its organoid and chromosome biology strengths toward translational platforms — expect future work at the intersection of 3D tissue models and genome architecture for drug discovery and disease modeling.
IMBA is overwhelmingly a project leader: 21 of 30 projects are self-coordinated, mostly individual ERC grants and MSCA fellowships that reflect a PI-driven, investigator-led research culture. Their 8 participant roles tend to be in larger collaborative consortia (REANIMA, EuroGCT, LifeTime, HCA Organoid) where they contribute specialized organoid or molecular biology expertise. With 95 unique consortium partners across 19 countries, they maintain a broad but non-dependent network — they attract collaborators to their capabilities rather than seeking consortium membership.
IMBA has worked with 95 unique partners across 19 countries, indicating a well-connected pan-European network. Their collaborative projects span major EU research hubs, though the institute's strength lies in attracting individual researchers via MSCA fellowships rather than building repeat-partner consortia.
IMBA is one of Europe's foremost organoid technology centers, with an unusually deep portfolio spanning cerebral, embryonic (blastoid), and tissue organoids — few institutes can match this breadth under one roof. Their combination of organoid expertise with chromosome biology and epigenetics creates a rare capability to study how genome architecture drives disease in 3D human tissue models. For consortium builders, IMBA offers both the fundamental science credibility of 6 ERC grants and practical translational assets like SLAMseq temporal transcriptomics and high-throughput organoid screening platforms.
